Sugammadex in anesthesia practice

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 16, 2010, Pages 2759-2771

  Duvaldestin, Philippe ^a   Plaud, Benoit ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Cyclodextrins; Monitoring; Neuromuscular blockade; Reversal; Rocuronium; Succinylcholine; Sugammadex; Vecuronium

Indexed keywords

ATRACURIUM; ATROPINE; BENZYLISOQUINOLINE DERIVATIVE; CHOLINESTERASE INHIBITOR; CYCLODEXTRIN; EDROPHONIUM; GLYCOPYRRONIUM BROMIDE; MIVACURIUM; MUSCLE RELAXANT AGENT; NEOSTIGMINE; PANCURONIUM; PROPOFOL; ROCURONIUM; SEVOFLURANE; SUGAMMADEX; SUXAMETHONIUM; TUBOCURARINE CHLORIDE; VECURONIUM;

ANESTHESIA; ANESTHESIA INDUCTION; BRADYCARDIA; BRONCHUS SECRETION; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSGEUSIA; ENDOTRACHEAL INTUBATION; ERYTHEMA; FLUSHING; GENERAL ANESTHESIA; HUMAN; HYPERKALEMIA; IN VIVO STUDY; INTESTINAL DYSMOTILITY; MUSCLE RELAXATION; NEUROMUSCULAR BLOCKING; NONHUMAN; POSTOPERATIVE NAUSEA AND VOMITING; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SALIVATION; SIDE EFFECT;

ANDROSTANOLS; ANESTHESIA; GAMMA-CYCLODEXTRINS; HUMANS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR NONDEPOLARIZING AGENTS;

EID: 78049388005     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.528391     Document Type: Review

References (70)

1. Egan TD, Kern SE, Johnson KB, et al. The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol ®) versus propofol in a lipid formulation (Diprivan ®): an electroencephalographic and hemodynamic study in a porcine model. Anesth Analg 2003;97:72-9
2. Bom A, Epemolu O, Hope F, et al. Selective relaxant binding agents for reversal of neuromuscular blockade. Curr Opin Pharmacol 2007;7:298-302
3. Griffith HR, Johnson GE. The use of curare in general anesthesia. Anesthesiology 1942;3:418-20
4. Duvaldestin P, Cunin P, Plaud B, et al. French survey of neuromuscular relaxant use in anesthetic practice in adults. Ann Fr Anesth Rean 2008;27:483-9
5. Chambers D, Paulden M, Paton F, et al. Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment. Health Technol Assess 2010;14:1-211
6. Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathological states: etiologic factors and molecular mechanisms. Anesthesiology 2006;104:158-61
7. Gronert GA. Cardiac arrest after succinylcholine: mortality greater with rhabdomyolysis than upregulation. Anesthesiology 2001;94:523-30
8. Berg H, Viby-Mogensen J, Engbaek J, et al. Residual block is a risk factor for postoperative pulmonary complications. A prospective, randomized and blinded study of postoperative complication after atracurium, vecuronium and pancuronium. Acta Anaesth Scand 1997;41:1095-10
9. Plaud B, Debaene B, Donati F, Marty J. Residual paralysis after emergence from anesthesia. Anesthesiology 2010;112:1013-22
10. Whittaker M. Plasma cholinesterase variants and the anesthetist. Anaesthesia 1980;35:174-97
11. Viby-Mogensen J. Clinical assessment of neuromuscular transmission. Br J Anaesth 1982;54:209-23
12. Fuchs-Buder T, Claudius C, Skovgaard LT, et al. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand 2007;51:789-808
13. Grayling M, Sweeney BP. Recovery from neuromuscular blockade: a survey of practice. Anaesthesia 2007;62:806-9
14. Debaene B, Plaud B, Dilly MP, et al. Residual paralysis in the PACU after a single intubating dose of nondepolarizing relaxant with an intermediate duration of action. Anesthesiology 2003;98:1042-8
15. Mc Caul C, Tobin E, Boylan JF, et al. Atracurium is associated with postoperative residual curarization. Br J Anaesth 2002;89:766-9
16. Hayes AH, Mirakhur RK, Breslin DS, et al. Postoperative residual block after intermediate-acting neuromuscular blocking drugs. Anaesthesia 2001;56:312-18
17. Kim KS, Lew SH, Cho HY, et al. Residual paralysis induced by either vecuronium or rocuronium after reversal with pyridostigmine. Anesth Analg 2002;95:1656-60
18. Murphy GS, Szokol JW, Marymont JH, et al. Residual paralysis at the time of extubation. Anesth Analg 2005;100:1840-5
19. Cammu G, De Witte J, De Veylder J, et al. Postoperative residual paralysis in outpatients versus inpatients. Anesth Analg 2006;102:426-9
20. Eriksson LI. Evidence-based practive and neuromuscular monitoring. It's time for routine quantitative assessment. Anesthesiology 2003;98:1037-9
21. Viby-Mogensen J, Jorgensen BC, Ording H. Residual curarization in the recovery room. Anesthesiology 1979;50:539-41
22. Eriksson LI, Sundman E, Olsson R, et al. Functional assessment of the pharynx at rest and during swallowing in partially paralysed humans. Anesthesiology 1997;87:1035-43
23. Sundman E, Witt H, Olsson R, et al. The incidence and mechanism of pharyngeal and upper esophageal dysfunction in partially paralyzed humans. Anesthesiology 2000;92:977-84
24. Claudius C, Viby-Mogensen J. Acceleromyography for use in scientific and clinical practice. A systematic review of evidence. Anesthesiology 2008;108:1117-40
25. Baillard C, Bourdiau S, Le Toumelin P, et al. Assessing residual neuromuscular blockade using accelerometry can be deceptive in postoperative awake patients. Anesth Analg 2004;98:854-7
26. Booij LHDJ. Cyclodextrins and the emergence of sugammadex. Anaesthesia 2009;64(Suppl 1):31-7
27. Cheng CR, Sessler DI, Apfel CC. Does neostigmine administration produce a clinically important increase in postoperative nausea and vomiting? Anesth Analg 2005;101:1349-55
28. Bom A, Bradley M, Camero K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002;41:266-70
29. Adam JM, Benett DJ, Bom A, et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide:synthesis and structure activity-relationships. J Med Chem 2002;45:1806-16
30. Zhang MQ. Drug-specific cyclodextrins: the future of rapid neuromuscular block reversal? Drugs Future 2003;28:347-54
31. Epemolu O, Bom A, Hope F, et al. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003;99:632-7
32. Gijsenbergh F, Ramael S, Houwing N, et al. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005;103:695-703
33. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex. Anesthesiology 2006;104:667-74
34. Sparr HJ, Vermeyen KM, Beaufort A, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study. Efficacy, safety and pharmacokinetics. Anesthesiology 2007;106:935-43
35. de Boer HD, Van Egmond J, Van de Pol F, et al. Sugammadex,a new reversal agent for neuromuscular block induced by rocuronium in the anesthetized Rhesus monkey. Br J Anaesth 2006;96:473-9
36. Shields M, Giovanelli M, Mirakhur RK, et al. Org25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006;96:36-43
37. Vanacker BF, Vermeyen KM, Struys MMRF, et al. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg 2007;104:563-8
38. Rex C, Wagner S, Spies C, et al. Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia. Anesthesiology 2009;111:30-5
39. Suy K, Morias K, Cammu G, et al. Effective reversal of moderate rocuronium or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 2007;106:283-8
40. Khuenl-Brady KS, Wattwil M, Vanacker CK, et al. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine, a multicenter, randomized, controlled trial. Anesth Analg 2010;110:64-73
41. Flockton EA, Mastronardi P, Hunter JM, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth 2008;100:622-30
42. Eleveld DJ, Kuizenga K, Proost JH, et al. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth Analg 2007;104:582-4
43. Plaud B, Meretoja O, Hojmockel R, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 2009;110:284-94
44. Duvaldestin P, Kuizenga K, Saldien V, et al. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium-or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia. Anesth Analg 2010;110:74-82
45. Groudine SB, Soto R, Lien C, et al. A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007;104:555-62
46. MCCourt KC, Salmela L, Mirakhur RK, et al. Comparison of rocuronium and suxamethonium for use during rapid sequence induction of anaesthesia. Anaesthesia 1998;53:867-71
47. FDA Anesthetic and Life Support Advisory Committee Meeting. Sugammadex Sodium Injection. (NDA 22-225). March 11, 2008. Briefing Document (Background Package). Organon USA. Available from: http://www.fda.gov/ohrms/dockets/ac/08/ briefing/2008-4346b1-02-Organon.pdf. [Last accessed 4 August 2010]
48. de Boer HD, Driessen JJ, Marcus MAE, et al. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex. Anesthesiology 2007;107:239-44
49. Puhringer FK, Rex C, Sielenkamper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points. Anesthesiology 2008;109:188-97
50. Lee C, Jahr JS, Candiotti KA, et al. Reversal of profund neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology 2009;110:1020-5
51. Staals LM, Snoeck MMJ, Driessen JJ, et al. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. Br J Anaesth 2010;104:31-9
52. Szenohradszky J, Fisher DM, Segredo N, et al. Pharmacokinetics of rocuronium (ORG 9426) in patients with normal renal function or patients undergoing cadaveric renal transplantation. Anesthesiology 1992;77:899-904
53. Cooper RA, Maddineni VR, Mirakhur RK, et al. Pharmacokinetics of rocuronium bromide in patients with and without renal failure. Br J Anaesth 1993;11:43-4
54. Proost JH, Eriksson LI, Mirakhur RK, et al. Urinary, biliary and faecal excretion of rocuronium in humans. Br J Anaesth 2000;85:717-23
55. Cammu G, De Kam PJ, Demeyer I, et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaesth 2008;100:373-9
56. de Kam PJ, van Kuijk J, Prohn M, et al. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation. A thorough QTc study. Clin Drug Investig 2010;30:599-611
57. A Randomized, double-blind, placebo-controlled, parallel-group study to evaluate the incidence of hypersensitivity after repeated single dose administrations of sugammadex in healthy subjects. Study P06042. Available from: http://clinicaltrials.gov/ct2/show/NCT00988065?term=sugammadex&-rank=3 [Last accessed 4 August 2010]
58. Bhananker SM, O'Donnell JT, Salemi JR, et al. The risk of anaphylactic reactions to rocuronium in the United States is comparable to that of vecuronium:an analysis of Food and Drug Administration reporting of adverse events. Anest Analg 2005;101:819-22
59. Dewachter P, Mouton-Faivre C, Emala CW. Anaphylaxis and anesthesia. Controversies and new insights. Anesthesiology 2009;111:1141-50
60. Baillard C, Korinek AM, Galanton V, et al. Anaphylaxis to rocuronium. Br J Anaesth 2002;88:600-2
61. Harboe T, Guttormsen AB, Irgens A, et al. Anaphylaxis during anesthesia in Norway:a six-year single-center follow-up study. Anesthesiology 2005;102:897-903
62. McNeil O, Kerridge RK, Boyle MJ. Review of procedures for investigation of anaesthesia-associated anaphylaxis in Newcastle, Australia. Anaesth Intens Care 2008;36:201-7
63. Miller RD. Will succinylcholine ever disappear? Anesth Analg 2004;98:1674-5
64. Lee C. Goodbye suxamethonium Anaesthesia 2009;64(Suppl 1):73-81
65. Arbous MS, Meursing AEE, Van Kleef JW, et al. Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology 2005;102:257-68
66. Blobner M, Eriksson LI, Scholz J, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anaesthesiol 2010;27:874-81
67. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology 2008;109:816-24
68. Lemmens HJ, El-Orbany MI, Berry J, et al. Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: sugammadex versus neostigmine. BMC Anesthesiol 2010;10:15
69. Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg 2007;104:569-74
70. Staals LM, Snoeck MMJ, Driessen JJ, et al. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth 2008;101:492-7